1Stamler J, Stamler R, Neaton JD, et al. Blood pressure, systolic and diastolic, and cardiovascular risks, CLS population data [J]. Arch InternMed, 1993,153(5) :598-615.
2Tomita N, Morishita R, Higaki J, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat ana'iotensinozen[ J]. Hvvertension, 1995,26( 1 ) : 131-136.
3Gyurko R,Wielbo D, Phillips MI. Antisense inhibition of AT, receptor mRNA and anglotensin mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenie origin[J].Regul Pept,1993,49(2):167-174.
4Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension anew strategy for renin-angiotensin candidate genes [J]. Kidney Int,1994,46(6) : 1554-1556.
5Ambuhl P, Gyurko R, Phillips MI. A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the anglotensin AT1 receptor[J]. Regul Pept, 1995,59(2) : 171-182.
6Mohan K, Sharon C, Wang H, et al.Targeting of the renin-angiotcnsin system by antisense gene therapy: a possible strategy for the tong-trem control of hypertension [J]. Hypertension, 2000,18 (4) : 352-362.
7Wang H, Reaves PY, Gardon ML, et ol. Angiotensin l-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR [J]. Hvoertension, 2000,35 ( 1 ) : 202-208.
8Phillips MI, Mohuezy-Dominiak D, Coffey M, et al. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1 R mRNA antisense[ J]. Hypertension, 1997,29( 1 Pt 2) :374-380.
9Raizada MK, Katovich MJ, Wang H, et al. Is antisense gene therapy a step in the right direction in the control of hypertension[J]. Am J Physiol, 1999,277 (2) : H423-432.
10Li P, Morris M. Diz DI, et al, Role of paraventricular angiotensin AT1 receptors in salt sensitive hypertension in mRen-2 transgenic rats[J].Am J Physiol, 1996,270(5 Pt 2) : 1178-1181.
二级参考文献57
1[1]Phillips MI. Antisense inhibition and adeno-associated viral vector deliverv for reducing hypertension[J]. Hypertension,1997,29:177-187
2[2]Burt VI,Whelton P,Roccella ET,et al. Prevalence of hypertension in the US adult population results from the third nattional health and nutrtion exammation survey[J ]. Hypertension, 1995,25: 305-313.
3[3]Phillips MI. Is gene therapy for hypertensiou possible[ J ]. Hvpertension1999,33:8-13.
5[5]Phillips MI. Somatic gene therapy for hypertension[J ]. Braz Med Biol Res.2000,30(6): 715-721.
6[6]Colige A,Sokolov BP. Cellular uptake and subcellular distribution of phos phorothioate oligonucleotides into cultured cells[J]. Antisensc Res Des.1992,2:211-222.
7[7]Wahletredt C. Antisense oligonucleotide strategies in neuropharmacology[J]. Trends Pharmacol Sci,1994,15:42-46.
8[8]Campbell JM,Bacon TA,Wickstrom E. Oligodeoxynucleotide phosphoroth ioate stability in cubcellular extracts, culture media, ser and cerebrpspinal fluid[J ]. J Biochem Biophys Methods, 1990,20: 259-267.
9[9]Loke SL,Stein CA,Zhang XH,et al. Characterization of oligonucleotidetransport into living cells[J]. Proc Natl Acad Sci USA, 1989,86: 3474-3478.
10[10]Iversen PL,Mata L,Tracewell WG,et al. Pharmacokineties of an antisensephysphorothioate oligodeoxynucleotide against rev from human immuno de ficiency virus type 1 in adult male rat following single injections and contin uous infusion[J]. Antisense Res Dev, 1994.4: 43-52.
9FRANKS P W, BHATTACHARYYA S, LUAN J,et al. Association between physical activity and blood pressure is modified by variants in the G-protein coupled receptor 10[J]. Hypertension, 2004,43 (2): 224-228.
10RAURAMAAR,KUHANENR,LAKKATA,et al. Physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism[J]. Physiol Genomics, 2002,14: 10(2):71-77.
